Biomedal and the Hospital Virgen del Rocío develop a by rub18840

VIEWS: 5 PAGES: 1

									Biomedal and the Hospital Virgen del Rocío develop a kit to prevent liver transplant
rejection.

Biomedal has developed, as part of a technology development project funded by the CTA
(Corporación Tecnológica de Andalucía) and the IDEA agency (Agencia de Innovación y
Desarollo de Andalucia), a kit that will allow to diagnose and control liver transplant
rejection due to de novo post-transplant immune hepatitis.

This kit, based on a scientific discovery from the Immunology Service of the University
Hospital Virgen del Rocío, may be a useful tool to prevent rejection of liver transplants, since
10% of transplants are susceptible to de novo post-transplant immune hepatitis, a disease
which has emerged as a major cause for organ rejection.

The kit, which offer an alternative that is less laborious and more sensitive than current
techniques, is being validated at the hospital Virgen del Rocio, Gregorio Marañón and Puerta
del Hierro (Madrid) and Clinic de Barcelona and has been acquired by international centers,
such as the Technion in Haifa (Israel) and Cedars-Sinai Medical Center in Los Angeles
(California, USA).

Scientists at the University Hospital Virgen del Rocío have applied for a patent for this kit,
Biomedal being the developer of the method and exclusive license holder for its
commercialization. The research team of the University Hospital Virgen del Rocío is studying
potential application in transplant rejection in other organs including kidney, and
haematopoietic stem cell transplantation.

Among the many factors contributing to the degeneration or rejection of a transplanted
organ, a team of doctors and scientists from the University Hospital Virgen del Rocío
identified a new type of hepatitis, called de novo immune post-transplant hepatitis. This
hepatitis requires immunosuppressive treatment, unlike viral hepatitis, which is usually
treated with immunostimulators, which would be counterproductive in the case of de novo
immune post-transplant hepatitis. Inadequate treatment associated with hepatitis can lead
to death. De novo immune post-transplant hepatitis is due to the fact that transplanted
patient do not have a specific protein (GSTT1) that it is present in the organ of the donor.
This causes the body of the transplanted patient to "reject" this protein, which means
generate antibodies against it, because it is recognized as a foreign body, leading to the
rejection of the organ. One in five people do not harbor the gene encoding this protein and
would be likely to reject the liver from a donor who possesses it.

Due to the fact that novo immune post-transplant hepatitis is not easily distinguishable
clinically from other hepatitis, the differential diagnosis is difficult and often requires biopsy,
an invasive procedure. The kit developed by Biomedal allows thanks to a fast, automated
and non-invasive method, the rapid detection of antibodies against the GSTT1 protein, which
indicates a risk for the patient to undergo this specific type of rejection.

Source: Corporación Tecnológica de Andalucía (CTA)
Thursday 30 July 2009

								
To top